Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 – Wolf Mirror

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition. This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation. A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Follow this link:
Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 - Wolf Mirror

Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI – Xconomy

XconomySan Diego

Two venture-backed startups that have developed technologies intended to speed up the drug discovery and development process are combining those tools in a bid to achieve their goals together.

San Francisco-based Atomwise has developed deep learning techniques for use in structure-based small molecule drug discovery. Since 2012 it has raised more than $50 million to bolster the development and application of its tech, which has been used by pharmaceutical and agrochemical companies, as well as by universities and hospitals across 40 countries. It says its computational tools can quickly analyze billions of compounds and thereby speed up the process of identifying compounds that bind to disease-causing proteins.

Stemonix, which has offices in Maple Grove, MN, and in San Diego, has developed models for testing potential drugs from human induced pluripotent stem cells, creating what it calls living microtissues to mimic human organs, including the brain and heart. The startup reported raising a $14.4 million Series B earlier this year to speed the commercialization of its platforms. Its MicroOrgans technology provides 3D disease models that the company hopes will give researchers a more accurate indication of whether compounds are likely to work in humans.

This is especially difficult to determine when it comes to finding drugs that work on rare neurological diseases, which are tricky to replicate in animal models because of the complexity of the human brain, according to Stemonix.

Atomwise has struck a number of deals with biotech and pharma companies interested in its tech, including Atropos Therapeutics, Hansoh Pharma, and Eli Lilly (NYSE: LLY). Financial terms of this latest deal werent disclosed.

The companies plan to use Atomwises AI and Stemonixs human MicroBrain 3D disease model to target Rett syndrome, a severe neurological disorder caused by mutations in the MECP2 gene. The gene encodes a protein thats needed for the development of the nervous system and normal brain function. Babies with the condition, most often infant girls, typically develop normally for the first 6 to 18 months of life before symptoms kick in. Then, they experience a progressive loss of motor skills and speech.

Some medications are used to ameliorate their symptoms, but no FDA-approved treatment exists. A number of companies are in human testing with experimental drugs for the condition.

Those in late-stage testing include Newron Pharmaceuticals, which is developing an experimental drug called sarizotan that aims to reduce patients episodes of apnea, or breathing disturbances, and San Diegos Acadia Pharmaceuticals, which last year licensed trofinetide, an investigational treatment targeting the disease, from Australias Neuren Pharmaceuticals.

The UKs GW Pharmaceuticals (NASDAQ: GWPH) is studying non-psychoactive parts of cannabis, including cannabidiol and cannabidivarin, as potential treatments.

Novartis (NYSE: NVS) subsidiary AveXis is also advancing a gene therapy for Rett, but in August said that its advancement to human testing would be delayed so it could redo and add to preclinical studies. The decision was made following revelations that some of the animal data the company submitted to the FDA in support of onasemnogene abeparvovec (Zolgensma), the gene therapy it developed for babies with spinal muscular atrophy, had been manipulated. Novartis acquired AveXis in 2018.

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

Read the original:
Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI - Xconomy

Story of a 15-year old scientist: How it all began – EuroScientist

Children and young adults these days have awide range of possibilities how to spend their leisure time. Some of us like to watch movies, some of us enjoy playing aflute and some of us prefer to go laboratories, put on a white coat and carry out an experiment. Zuzana Hudov, a15-year old student from Slovakia, fell into the category of teenagers who preferred going to labs and make experiments. Even though this is just onestory it once may be astory of hundreds of young aspiring students.

As alittle child Zuzanawas not much different from all the other kids in the kindergarten. Shewas playful, energetic and endlessly curious about the world surrounding her. However, curiosity diverted from the behaviour of her classmates. Most of the kids liked to explore the outside world, yet Zuzanawas more fascinated about the things that could not be understood by just looking at them. Shewould spend hours and hours browsing through an old Encyclopedia, looking at the pictures of human body, homogenesis phases and even insect behaviour. Her restless mind caused her agreat deal of problems in kindergarten since sheoften refused to go to bed during the afternoon sleep-time and, often, she would even take abook from the small kindergarten library and read it, hidden under the duvet, while other kids were sleeping. When Zuzana was five, her mother realised that the kindergarten was noplace for her daugther, and therefore, with the approval of experts, Zuzana was admitted to primary school ayear earlier than regular . That was where the real journey started, says Zuzana.

The competitive atmosphere of school brought Zuzanas ambitions and her desire to thrive to life. Even though shewas more than ayear younger than her classmates, she always perfomed very well and was one of the best pupils in her class. Although Zuzanastill preferred to read books, shefelt aresponsibility for the community and mediated with teachers and pupils about potential improvements to make; therefore she was electedclass representative.

Until the age of eleven her hobbies were pretty general: reading, playing the piano and dancing. Zuzanas interests changed when she was in sixth grade, as at that time, biology and chemistry classes were added to school curriculum. Zuzana was fascinated by the two new subjects and used to spend several hours each day to read popular science books and magazines. At the age of twelve sheperformed her first study about human body mass index (BMI) and obesity and took part in a local competition.

Due to her ambition and success in and outside school, she got the chance to study at GBAS Suany, aprestigious Slovak bilingual grammar school, where she started at the age of thirteen, and joined classes with classmates 3 years older than her.

During the biology classes, especially on the topics of neuroscience and genetics, Zuzana realised that although her desire for more knowledge was being fulfilled, her ambitions to do her own investigations and actuallycontribute to science were not satisfied. While looking for opportunities to collaborate with reasearch labs, she discovered that in many Western countries it is not uncommon for youngstudents to doscientific internships. She started contacting research institutions in Slovakia, but never was selected because of her young age. Consequently she started to applyoutside her home country and was eventually accepted as a summer intern at Masaryk University in Brno, Czech Republic at the Department of Histology and Embryology.

The laboratories that gave Zuzana this opportunity was lead by Mgr. Da Bohaiakov, Ph.D. and focused on neurogenesis research. The project she worked on was the immunofluorescent analysis of in vitro neural rosette formation from induced pluripotent stem cells (iPSCs). The aim of her research was to analyse the markers of neural rosette formation, which is a2D in vitro model of human neurogenesis. During the neurulation phase of embryogenesis there are many things than may go wrong, which can lead to neural tube defects (NTDs), such as spina bifida. NTDs are very dangerous and cause alot of pain and suffering in an individuals life. However, these days we are not only unable to treat these disorders, but we are not even able to observe the neurulation process non-invasively. That is why scientists are trying to developwith the in vitro solutions, which neural rosettes might potentially be.

Zuzanas first laboratory internship marked some new beginnings in her life such as the her first successfull research project, and afirst scientific work that won the 3rd place at the national Stredokolsk Odborn innos (High School Scientific Activity). At the age of 15 shewas the youngest participant in history.

The success of her first project was the incentive for Zuzanato participate in more scientific activities; therefore during the following term she launched abiology club at her school, took part in an international DNA essay contest where she finished among the top ten participants and carried out more work in a laboratory and completed one more internship.

In spite of all her success Zuzana still feels the responsibility for her community and she thinks that if shecould achieve all of this, why not any other student in the world? This is the reason why she decided to publish her story

Iam certainly no better than any other child, she says, yet Iwas lucky, Ihad an idea and enough passion not to give up, even though the circumstances were against me.

Zuzana hopes that her story can motivate her fellow pupils and she urges parents to foster the curiosity and ideas of their children. Additionally she wants to send the message that is importnat to look outside your own surrounding and use the possibilities Europe of today gives to everyone.

By Zuzana Hudacova

Featured image credit: Zuzana Hudov

Like Loading...

Related Posts

Go here to see the original:
Story of a 15-year old scientist: How it all began - EuroScientist

Cellex Opens New Plant to Manufacture Innovative Cell Therapy Products for Cancer – PRNewswire

COLOGNE, Germany, Dec. 5, 2019 /PRNewswire/ -- Cellex has opened a new Cell Manufacturing Plant in Cologne, Germany that will be the focal point for the production of innovative cell therapy products (e.g. CAR-T cells) as targeted treatments for different types of cancers and other diseases. The new facility has doubled the company's manufacturing capacity. Reasons for the expansion include the rising global demand and worldwide bottlenecks in production, as well as a considerable amount of promising research on new treatment approaches for various types of cancer. With this expansion, Cellex has laid the groundwork to provide comprehensive support to patients all over the world who are dependent on new therapies for the treatment of serious diseases. The facility offers more than 800 square meters of floor space and contains a clean room laboratory and other rooms for manufacturing and quality control.

At the new Cell Manufacturing Plant, advanced therapy medicinal products (ATMPs) such as CAR-T cells are produced using state-of-the-art methods including magnetic selection, cell purification, cryopreservation and cell-based efficacy tests. Other services include long-term cryo-storage for ATMPs. Through international partnerships, Cellex is already operating at a global level and is expecting to see growth in worldwide demand for its products. In addition to specialized expertise in manufacturing cell therapy products, the company also operates collection centers for stem cell and bone marrow donations as well as a CellCommunity for the donation of cells to science and research all over the world.

The Cellex Group was founded in 2001 with a primary focus on the collection of stem cells and bone marrow. Today, the Cellex Collection Center is the world's largest and most experienced collection center for allogeneic blood stem cell and bone marrow donations. Furthermore, Cellex has grown into an important full service provider for other companies in the production of innovative cellular therapy products (e.g. CAR-T cells). Since 2014, the company has been working on the development of its own innovative CAR-T cells and bispecific antibodies for the treatment of cancer in collaboration with its Dresden-based affiliate, GEMoaB.

During the opening ceremonies, Prof. Dr. Gerhard Ehninger, founder and owner of Cellex, pointed to the encouraging possibilities offered by CAR-T cell therapies being developed by Cellex. "Battling cancer with CAR-T cells specifically targeted against tumor cells is one of the most promising treatment approaches today. However, CAR-T cells developed so far harbor various risks, such as excessive cytokine release or the development of resistances. Therefore, we are now collaborating with our affiliate, GEMoaB, to develop new platforms that are easier to control such as bispecific antibodies or UniCAR cells, which are currently undergoing initial testing."

About Cellex

Cellex wants to help people suffering from serious diseases through stem cell donations, but also through innovative treatment options. Cellex develops, tests and establishes new therapy approaches for people with cancer. These new cutting-edge medicines are manufactured by Cellex at the company's Cell Manufacturing Plant.

The Cellex Collection Center is the largest and most experienced collection center for allogeneic blood stem cells and bone marrow in the world. More than 55 percent of all stem cell donations in Germany are collected by Cellex. In addition to the manufacturing of cell therapy products, Cellex is involved in research for new cell products and collaborates with a large number of other companies.

Media Contact

Julia Bose, Head of Marketing & CommunicationsTelephone: +49-221-4545-916E-mail: j.bose@cellex.me

SOURCE Cellex GmbH

Go here to read the rest:
Cellex Opens New Plant to Manufacture Innovative Cell Therapy Products for Cancer - PRNewswire

Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It? – Kaiser Health News

A lack of a uniform policy allows convicted and accused perpetrators to access some dating apps and leaves users vulnerable to sexual assaults, according to an investigation. Public health news is on stem cell heart therapy, flu season, Parkinson's disease, poetry therapy, problems with blood-sugar monitors, warnings about ski helmets, a grateful transplant patient, children prone to violent outbursts, and more.

ProPublica:Tinder Lets Known Sex Offenders Use The App. Its Not The Only One.Susan Deveau saw Mark Papamechails online dating profile on PlentyofFish in late 2016. Scrolling through his pictures, she saw a 54-year-old man, balding and broad, dressed in a T-shirt. Papamechail lived near her home in a suburb of Boston and, like Deveau, was divorced. His dating app profile said he wanted to find someone to marry. Deveau had used dating websites for years, but she told her adult daughter the men she met were dorky. (Flynn, Cousins and Picciani, 12/2)

The Washington Post:Benefits Of Stem Cell Heart Therapy May Have Nothing To Do With Stem Cells, A Study On Mice SuggestsFor 15 years, scientists have put various stem cells into seriously ill patients hearts in hopes of regenerating injured muscle and boosting heart function. A new mouse study may finally debunk the idea behind the controversial procedure, showing the beneficial effects of two types of cell therapy are caused not by the rejuvenating properties of stem cells, but by the bodys wound-healing response which can also be triggered by injecting dead cells or a chemical into the heart. (Johnson, 11/27)

The Associated Press:Flu Season Takes Off Quickly In Deep South StatesThe flu season is off and running in the Deep South. The most recent weekly flu report from the Centers for Disease Control and Prevention finds high levels of flu-like illness in Alabama, Arkansas, Georgia, Nevada, South Carolina and Texas. The highest level in that report for the week ended Nov. 16 was in Mississippi. Doctors in the Magnolia State say theyre already seeing lots of patients. (11/29)

The New York Times:Swimmers Beware Of Deep Brain StimulationA lifelong swimmer leapt into deep water near his lakeside home, and was horrified to find himself completely unable to swim. Had his wife not rescued him, he might have drowned. He had recently received an electronic brain implant to control tremors and other symptoms of Parkinsons disease, and somehow the signals from the device had knocked out his ability to coordinate his arms and legs for swimming. (Grady, 11/27)

The Wall Street Journal:A Prescription Of Poetry To Help Patients Speak Their MindsDr. Joshua Hauser approached the bedside of his patient, treatment in hand. But it wasnt medicine he carried. It was a copy of a 19th-century poem titled Invictus. It isnt often that doctors do rounds with poetry. But Dr. Hauser, section chief of palliative care at the Jesse Brown VA Medical Center, and colleagues are testing it as part of a pilot study. He entered Mr. Askews room. The patient had asked for Invictus, a dark poem by William Ernest Henley that he remembered from his past. (Reddy, 12/1)

The Wall Street Journal:Diabetes Patients Blood-Sugar Data Arent Being SharedParents of young diabetes patients say they havent been getting crucial readings from blood-sugar monitors worn by their children since early Saturday. The technological breakdown, the origin of which isnt certain, threatens the proper care of the young diabetes patients. (Loftus, 12/1)

The New York Times:Study Warns Helmets Dont Offer Full Protection On SlopesCONCORD, N.H. For several years now, it has been almost de rigueur for skiers and snowboarders to strap on a helmet amid rising concerns about safety on the slopes. But a new study caution that helmets cannot protect skiers from all head injuries. (11/28)

Kaiser Health News:For Artist Inspired By Illness, Gratitude Outweighs PainPeople often ask Dylan Mortimer how it feels to breathe through transplanted lungs. He gets that a lot because while most people go through life with one pair of lungs, Mortimer is on his third. The 40-year-old artist has endured two double lung transplants in the past two years. He often shares his journey onstage as a speaker. But when the curtain closes, he leaves the rest of the storytelling to art. Im alive because of what someone else did, Mortimer said. That is humbling in all the best ways. (Anthony, 12/2)

NPR:Teens Who Threaten And Hit Their Parents: That's Domestic Violence TooNothing Jenn and Jason learned in parenting class prepared them for the challenges they've faced raising a child prone to violent outbursts. The couple are parents to two siblings whom they first fostered as toddlers and later adopted. In some ways, the family today seems like many others. Jenn and Jason's 12-year-old daughter is into pop star Taylor Swift and loves playing outside with her older brother. (Herman, 11/29)

NPR:Give Thanks For Adult Siblings And The Ties That BindWe didn't expect to need the card table for spillover seating at this year's Thanksgiving dinner. We would be fewer than usual, just nine altogether, and the littlest one's high chair needs no place setting. As we got things ready, I felt deep gratitude for the family members who would be here my husband, our two daughters, their husbands, my sister-in-law's 90-year-old mother and our two delightful granddaughters. But I also knew I would deeply miss the ones who couldn't make it. (Henig, 11/28)

The Washington Post:Doctors In China Found Tapeworms In Brain Of Man Who Ate Undercooked Meat In Hot PotA Chinese man sought medical attention for seizures and a headache that lasted nearly a month. Doctors found that tapeworms from undercooked meat were causing his pain. Researchers at the First Affiliated Hospital of Zhejiang University published a paper last week that details the plight of 46-year-old construction worker Zhu (an alias for the patient) in the eastern Zhejiang province of China who bought pork and mutton about a month ago for a spicy hot pot broth. (Beachum, 11/27)

Visit link:
Hidden Dangers Of Dating Apps: Sex Offenders, Including Rapists, Are Using Them. Why Do Companies Allow It? - Kaiser Health News

How cancer cells grow and spread in colon tissue? – Tech Explorist

Scientists from the Duke University Medical Center have observed how stem cell mutations quietly emerge and spread all through a broadening field of the colon until they eventually prevail and become a malignancy.

Scientists tried an innovative modeling system called molecular dyeing technique on mice to visually tag colon cancer mutations by causing stem cells to glow. Mutations found in colon cancer were then envisioned in the animals, enlightening a kind of tournment-to-the-death underway in the intestine in which some mutation beat the others to turn into the main impetus of a malignancy.

Joshua Snyder, Ph.D., assistant professor in the departments of Surgery and Cell Biology at Duke and corresponding and co-senior author of a study, said, This study provides new insight into the previously invisible process in which mutant precancerous stem cells spread throughout the colon and seed cancer. Our technique sets a firm foundation for testing new therapies that interrupt this new, pre-malignant process. We hope to one day target and eliminate these stealth precancerous cells to prevent cancer.

The technique that was applied uniquely tagged several common colon cancer mutations in the stem cells of a single tumor to create a fluorescent barcode. When transferred to a mouse, the rainbow of fluorescent stem cells could be visually tracked, revealing the cellular and molecular dynamics of pre-cancerous events.

In this way, the researchers found key differences in how the intestinal habitats typical to babies and adults grow pre-cancerous fields of mutant cells. At a critical period, newborns are sensitive to the effects of mutations within intestinal stem cells.

This insidiously seeds large fields of premalignant mutated cells throughout the intestine a process called field cancerization that dramatically increases cancer risk. These fields of mutated cells can grow and spread for years without being detected by current screening technologies; often, they remain harmless, but under proper conditions, they can rapidly become cancerous later in adults.

Scientists also found that some mutations can cause a striking increase in the fertility of the environment surrounding precancerous fields. At last, this prompts the rapid spread of areas throughout the intestine, with lethal outcomes.

Specific common mutations that arise from external sources, such as an injury or an environmental exposure, could also disrupt the environment surrounding the stem cell and lead to the rapid growth and spread of precancerous fields. These occurrences can be especially lethal in adults and occur much more rapidly than previously expected as if dropping a match on a drought-stricken forest.

Synder said, Field cancerization has been suggested to be the defining event that initiates the process of cancer growth, including cancers of the breast, skin, and lung. Our technique allows us to model how premalignant cells compete and expand within a field by simple fluorescent imaging, potentially leading to earlier diagnosis and treatment.

Additional studies are underway using the fluorescent barcoding to view the cancer fields in breast cancer, aiming to learn more about when malignant vs. benign mutations drive a pre-cancerous condition known as ductal carcinoma in situ.

The study is published online in the journal Nature Communications.

Read this article:
How cancer cells grow and spread in colon tissue? - Tech Explorist

Analysis Shows Need for Better Classification of Rare Lymphoma – Patch.com

New Brunswick, N.J. - December 4, 2019 In what is believed to be one of the largest studies of a rare disorder known as primary cutaneous gamma delta T-cell lymphoma (PCGDTCL), Rutgers Cancer Institute of New Jersey investigators and other collaborators examined characteristics, treatment patterns and outcomes of the disease, and determined accurate diagnosis of the disease requires ongoing analysis. Results of the work are being shared as part of a poster presentation at the American Society of Hematology Annual Meeting in Orlando this week by lead investigator Kevin David, MD, hematologist/oncologist at Rutgers Cancer Institute. Dr. David, who is also an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, shares more about the work.

Q: Why is this topic important to explore?

A: Primary cutaneous gamma delta T-cell lymphoma is a rare disorder, and in comparison to other more common subtypes of non-Hodgkin lymphomas, relatively little is known about prognostic factors and optimal treatments. Although it is a rare condition, it can in many instances behave quite aggressively and profoundly impact patients. Therefore, learning more about how this disease behaves, which disease characteristics affect outcomes, and which treatments may improve outcomes are all important to understand more fully.

Q: Tell us about the work and what you and your colleagues found.

A: Given the rarity of this particular lymphoma, collaboration with lymphoma researchers across the country was key in this study. We identified cases of PCGDTCL at 10 U.S. medical centers that occurred between 2000 and 2017, and collected information about patient characteristics, pathology characteristics, treatments administered, and outcomes, including remission rates and the length of time the disease was controlled. Although it is ideal for lymphomas to be diagnosed with uniform standards across the country, we found important nuances in the manner in which pathologists at different medical centers diagnose this rare lymphoma. Identifying these differences will be key to better streamline diagnoses in the future. We also found that patients in better overall health, as measured by the ECOG Performance Status scale, and with normal, as opposed to increased, levels of a tumor marker (lactate dehydrogenase) had better outcomes.

There is no one standard treatment regimen for this lymphoma, and a wide variety of treatments were used for newly diagnosed patients, ranging from ultraviolet light treatment to multi-agent chemotherapy. While no single treatment regimen resulted in the best outcomes, our results suggest that incorporating allogeneic stem cell transplant in treatment planning can improve results.

Q: Why are these results significant?

A: Our findings demonstrate the importance of trying to create and adhere to more uniform diagnostic criteria for this rare lymphoma. Additionally, we have much work to do in identifying better treatment regimens to improve outcomes for PCGDTCL, and continued multi-center collaborations will be crucial.

Aside from David, other authors on the work are Melissa Pulitzer, MD, Memorial Sloan Kettering Cancer Center; Joan Guitart, MD, and Maria Estela Martinez-Escala, MD, both Northwestern University Feinberg School of Medicine; Sharmir Geller, MD and Yaqun Wang, both Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; N. Nora Bennani, MD and Kay M. Ristow, BS, both Mayo Clinic; Daniel J. Landsburg, MD Abramson Cancer Center; Nicole Winchell and Paul Haun, MD, both University of Pennsylvania; Pamela Allen, MD, MSc, Emory University Winship Cancer Institute; Basem M. William, MRCP, MD, The Ohio State University James Comprehensive Cancer Center; Nathan Denlinger, MS, DO, Ohio State University Exner Medical Center; Neha Mehta-Shah, MD, Washington University; Ryan A. Wilcox, MD, PhD, University of Michigan Cancer Center; Alexandra Hristov, University of Michigan; Tatyana A. Feldman, MD and Alex Weller, Hackensack University Medical Center, New Jersey; Andrew M. Evens, DO, MSc, Rutgers Cancer Institute and Steven M. Horowitz, MD Memorial Sloan Kettering Cancer Center. Author disclosures and other details can be found here: https://ash.confex.com/ash/2019/webprogram/Paper130223.html.

###

Continued here:
Analysis Shows Need for Better Classification of Rare Lymphoma - Patch.com

Aledo and Ennis will be a legendary regional final matchup, and not because of what’s on the playing field – The Dallas Morning News

Aledo head coach Tim Buchanan was asked, moments after last Fridays 34-14 win over Red Oak, about how excited he was to get to the regional final.

The Bearcats coach flashed a smile and then started laughing once he realized who hed be facing in the regional final.

Now we get to play a damn legend in Sam Harrell, Buchanan said.

Harrell is the head coach at Ennis, which shut out Frisco 17-0 in the regional semifinals to advance to face Aledo, the reigning 5A-II state champions. The two teams play Friday at 7:30 p.m. at the Ford Center at The Star in Frisco.

On the field, it figures to be a quality matchup. Ennis, with only one loss to its name, is averaging 33.5 points per game while allowing 13.5. Aledo, on the other hand, is averaging 53.8 points per game while allowing just under 17. Its only loss was a three-point defeat to 6As Denton Guyer, which is also playing in a regional final this weekend.

The matchup on the sidelines, however, may be more interesting. Buchanan and Harrell are both in their second tenures at their respective schools.

Buchanan (239-52-3) is known as the architect of Aledos dynasty. He won five state championships as the schools head coach before he moved full-time into the districts athletic director position after the 2013 season. Once he turned in his whistle, he said he missed it. So, when the possibility of returning to the sideline became available this offseason, he jumped, swapping places with former Aledo head coach Steve Wood.

Harrell (206-65) is in his second season back at Ennis. The former Big Lake head coach took over at Ennis in 1994, leading the Lions to three state championships in the early 2000s. Multiple sclerosis forced him to retire after the 2009 season, but after stem cell treatment and a couple of trips to Panama, he ultimately made it back to the sidelines. He took Ennis back over in 2018, and after a 5-5 season a year ago, Harrell has the Lions back on the precipice of playoff glory.

Eight state championships and 445 wins isnt a bad combination for two head coaches facing off against each other in the regional final. Some may call it legendary. At least thats what Buchanan says about Harrell.

Ive never beat Sam, Buchanan said, adding that the two have known each other for a long time, so that will be fun, getting to play Coach Harrell again.

See the original post:
Aledo and Ennis will be a legendary regional final matchup, and not because of what's on the playing field - The Dallas Morning News

Engelhardt named 2019 Fellow of the National Academy of Inventors – Iowa Now

The National Academy of Inventors (NAI) has named University of Iowa cystic fibrosis and gene therapy researcher John Engelhardt, PhD, a 2019 Fellow.

Engelhardt, who is professor and head of anatomy and cell biology in the UI Carver College of Medicine and director of the UI Center for Gene Therapy, is recognized for his work in developing gene therapies to treat cystic fibrosis (CF). He will receive the award during an induction ceremony at the Heard Museum in Phoenix, Arizona, on April 10, 2020.

Engelhardts research primarily focuses on the molecular basis of CF, a progressive, inherited disease that causes persistent lung infections and other complications. CF is caused by well-studied mutations in a single gene, and Engelhardt has worked to develop gene therapy and gene editing methods to help treat the condition.

He also develops viral vector systems and animal models to test these methods and ultimately improve gene delivery. The animal models his laboratory has created are used by over 80 CF researchers, and he recently renewed a Research and Resource Center, funded by the National Institutes of Health (NIH), to continue this service to the research community and biotechnology companies that are developing therapies for CF and other lung diseases.

Engelhardt additionally studies airway stem cell niches, or the regulatory mechanisms that control stem cell growth and repair in the lungs, and has developed stem cell therapies for CF.

He currently holds 12 issued US patents, 41 issued foreign patents, and has 23 active patent applications. His patents and applications have been licensed to six companies, including two start-ups and a Fortune 100 company. Engelhardt provides critical tools and assistance to other researchers and companies in the field of CF research, and he is sponsored by the Cystic Fibrosis Foundation.

Engelhardt co-founded the gene therapy company Talee Bio, which was sold and is now Spirovant Sciences. The Philadelphia-based company was recently a part of a $3 billion deal to enhance the development of gene therapies for CF and other genetic diseases. Engelhardt remains on the scientific advisory board for Spirovant Sciences and serves as a key advisor as new therapies are created and tested.

NAI President Paul Sanberg says Engelhardt was selected for induction as he has demonstrated a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development, and welfare of society.

The University of Iowa Research Foundation (UIRF) nominated Engelhardt for this award to recognize his impact on creating and broadly commercializing gene therapies and his mentoring of other entrepreneurs on campus.

John has an extensive portfolio of intellectual property for advancing the commercialization of gene therapies, said Marie Kerbeshian, executive director of UIRF and an assistant vice president in the Office of the Vice President for Research. Not only is he a successful entrepreneur, as a UI researcher he is a key supporter of other researchers and other companies as they seek cures for cystic fibrosis.

He is one of 168 distinguished academic inventors across 136 research universities and institutes worldwide to join the academy this year. To date, NAI Fellows hold more than 41,500 issued U.S. patents, and the 2019 class includes six recipients of the U.S. National Medal of Technology & Innovation and U.S. National Medal of Science, four Nobel Laureates, among other honors.

We are very proud to see Dr. Engelhardts innovative and groundbreaking work recognized nationally, said Brooks Jackson, MD, MBA, UI vice president for medical affairs and the Tyrone D. Artz Dean of the UI Carver College of Medicine. He is a pioneer in his field and has set a prime example of how dedication and collaboration can lead to major advances in finding treatments for debilitating diseases.

Engelhardt is the second UI faculty member to join the academy, after UI neurosurgeon Matthew Howard, MD, was named a 2018 fellow for his work in developing brain and spinal cord neuromodulation devices.

Engelhardt joined the UI faculty in 1997 and is the Roy J. Carver Chair in Molecular Medicine and director of the Center for Gene Therapy of Cystic Fibrosis, which has received funding from the NIH continuously over the past 20 years. He earned a doctoral degree in human genetics from Johns Hopkins University and was a post-doctoral fellow at the University of Michigan. He has published 263 articles and book chapters, and has received over $74 million dollars in NIH grant support for his research.

Link:
Engelhardt named 2019 Fellow of the National Academy of Inventors - Iowa Now

The Making of a Root – Duke Today

DURHAM, N.C. -- When most people think of a plant, they picture stems, leaves, flowers, and all the parts that are visible above ground. But Duke biologist Philip Benfey is more interested in the hidden half of the plant that is buried beneath the soil. Roots: they may be out of sight, Benfey says, but they play critical roles, anchoring the plant and taking up water and nutrients.

Now, Benfey and colleagues Masashi Yamada and Xinwei Han have pieced together new details in the cascade of events that guide root growth -- research that could lead to more productive crops optimized for different soil types.

As a root tunnels through the soil, stem cells in the roots tip must determine whether to divide and producemore of the same stem cells, or differentiate into other cell types, based on their location within the root tissue. In a study published in the journal Nature, the researchers show that cells get some of the information they need from substances that are usually thought to be harmful.

Natural byproducts of cellular respiration, molecules called reactive oxygen species have long been described as stress signals that can cause tissue damage if left unchecked. But they also play a role in cell signaling, Benfeys work shows.

In a study of the small flowering plant Arabidopsis thaliana, the researchers report that root growth is partly regulated by interactions between two types of reactive oxygen species, superoxide and hydrogen peroxide, as they build up in different regions of the root tip.

What we did was map out, from signal to response, how these supposedly toxic chemicals are harnessed for a signaling process, Benfey said.

Roots grow longer thanks to a small region of stem cells at the end of each root that produces a constant supply of new cells behind it, propelling the root tip further downward through the soil like the head of a bullet. The daughter cells that are left behind stay put, and eventually stop dividing and start to specialize.

How fast a root grows depends on the balance between two opposing cues: those that encourage these stem cells to keep multiplying, and those that tell them to put the brakes on proliferating and change gears to specialize. The researchers identified a protein called RITF1 that, when activated, triggers this developmental switch.

The protein works by controlling where the two reactive oxygen species concentrate within the growing tip of the root.

These chemical signals tell the surrounding cells what course of action to take next. Cells exposed to higher amounts of superoxide keep dividing and producing new cells, while those that get a heavy dose of hydrogen peroxide differentiate, with a zone of transition where the two overlap.

We dont have all the pieces yet, Benfey said, but there are a lot more steps of the process that are now known through this work than were known before.

Reactive oxygen species arent just toxic chemicals, Benfey said. They serve important roles as regulators of a developmental process, going from a stem cell to fully differentiated tissue.

This research was supported by the Howard Hughes Medical Institute, the Gordon and Betty Moore Foundation (GBMF3405), and the U.S. National Institutes of Health (MIRA 1R35GM131725).

CITATION: "RGF1 Controls Root Meristem Size Through ROS Signalling," Masashi Yamada, Xinwei Han, Philip N. Benfey. Nature, December 4, 2019. DOI: 10.1038/s41586-019-1819-6

Read this article:
The Making of a Root - Duke Today